BD Announces $110 Million to Support U.S. Pharmaceutical Supply Chain for Biologic Drugs

Core Insights - BD (Becton, Dickinson and Company) is investing $110 million to expand its production of prefillable syringes in Columbus, Nebraska, which will create approximately 120 new jobs and enhance supply resilience within its Pharmaceutical Systems portfolio [1][4]. Investment Details - The investment includes $100 million for establishing BD Neopak™ Glass Prefillable Syringe production, with supply expected to begin in mid-2026 [4]. - An additional $10 million will be allocated to enhance cannula manufacturing capabilities at the Columbus site [4]. - This expansion follows a previous investment of over $35 million to expand prefilled flush syringe manufacturing, which will add approximately 50 new jobs [5]. Product Features - The BD Neopak™ Glass Prefillable Syringe platform is designed to meet the complex needs of biologics and combination products, available in 1 mL and 2.25 mL formats [2]. - It supports high viscosity formulations and is compatible with various drug-container integrations, facilitating seamless use with autoinjectors for patient-centric drug delivery [2]. Strategic Importance - This investment is part of BD's long-term growth strategy to strengthen its American manufacturing footprint and support U.S.-based drug delivery innovation [3][6]. - The move aims to build a more resilient pharmaceutical supply chain in the U.S., ensuring continuity and speed to market for injectable therapies as demand for biologics rises [6][7]. Company Commitment - BD is committed to investing over $2.5 billion in U.S. manufacturing capabilities over the next five years, reinforcing its position as the largest medical device manufacturer in the United States [5].